Immunological Studies on Modified Enzymes

Publisher Website
Google Scholar
Abstract
For the successful administration of exogenous proteins and enzymes for therapeutic purposes, abrogation or modifications of antigenicity and immunogenicity of the protein must be achieved without substantial loss of the biological activity necessary for therapeutic purposes. To try this, a model experiment was carried out. Escherichia coli L-asparaginase, whose chemical properties have been well defined and which is used for the treatment of acute lymphocytic leukemia and malignant lymphomas, was modified by copolymerization with isologous albumin; alterations of its immunogenicity were examined in mice. The immunogenicity of the modified L-asparaginase was remarkably reduced and satisfactory enzyme activity was preserved. [The successful application of exogenous proteins and enzymes for therapeutic purposes is limited by a number of problems, particularly those resulting from immunologic and allergic responses.].

This publication has 12 references indexed in Scilit: